Adjuvance Technologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2009-07-08
- Employees
- 11
- Market Cap
- -
Pertussis Acellular Vaccine Adjuvanted With TQL1055
Phase 1
Terminated
- Conditions
- Pertussis
- Interventions
- Other: TQL1055Biological: Acellular pertussis vaccine
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Adjuvance Technologies, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04793620
- Locations
- 🇦🇺
Q-Pharm, Brisbane, Australia
© Copyright 2025. All Rights Reserved by MedPath